Bio Roundup: FDA Says No, PCSK9 Value Fight, CRISPR Intrigue & More
Xconomy
AUGUST 19, 2016
All those years of hard work to reach the promised land, then just as a drug owner is ready to spike it home and take a victory lap, the FDA’s hands rise over the net… OK, it’s not a perfect analogy, but it’s better than comparing the patent fight over the gene editing system CRISPR-Cas9 to table tennis. (Be
Let's personalize your content